表紙
市場調查報告書

人工關節感染疾病:開發中產品分析

Prosthetic joint infections - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 410971
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
人工關節感染疾病:開發中產品分析 Prosthetic joint infections - Pipeline Review, H2 2019
出版日期: 2019年12月16日內容資訊: 英文 51 Pages
簡介

人工關節感染疾病 (PJI)是人工關節移植的尤其最嚴重的併發症之一。症狀是關節的疼痛和發硬、腫、患部週邊的皮膚發紅,疲勞及發熱等。作為危險因素,有年齡,以前的關節形成術,營養不良狀態,肥胖,糖尿病及進行的HIV疾病等。治療為抗菌療法。

本報告提供人工關節感染疾病的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等。

最新的新聞和發表

簡介

  • 調查範圍

人工關節感染疾病 概要

治療藥的開發

  • 開發中產品;概要

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

開發治療藥的企業

  • Cempra Inc
  • Motif Bio Plc
  • Nabriva Therapeutics AG
  • Telephus Medical LLC

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11683IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prosthetic Joint infections - Pipeline Review, H2 2019, provides an overview of the Prosthetic Joint infections (Musculoskeletal Disorders) pipeline landscape.

Prosthetic joint infection (PJI) is one of the most serious complications of prosthetic joint implantation. Symptoms include pain or stiffness in joints, swelling, redness around the wound, fatigue and fever. Risk factors include age, prior arthroplasty, poor nutritional status, obesity, diabetes mellitus and advanced HIV disease. Treatment includes antimicrobial therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prosthetic Joint infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prosthetic Joint infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 1 and 5 respectively.

Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prosthetic Joint infections (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prosthetic Joint infections (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Prosthetic Joint infections - Overview
  • Prosthetic Joint infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Prosthetic Joint infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Prosthetic Joint infections - Companies Involved in Therapeutics Development
    • Armata Pharmaceuticals Inc
    • Arrevus Inc
    • ContraFect Corp
    • Lumobiotics GmbH
    • Peptilogics Inc
    • Sonoran Biosciences Inc
    • Telephus Medical LLC
    • TenNor Therapeutics Ltd
  • Prosthetic Joint infections - Drug Profiles
    • (tobramycin + vancomycin SR) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APSA-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APSA-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-296 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fusidic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLG-0206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Oncology and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TNP-2092 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPH-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Prosthetic Joint infections - Dormant Projects
  • Prosthetic Joint infections - Discontinued Products
  • Prosthetic Joint infections - Product Development Milestones
    • Featured News & Press Releases
      • Oct 15, 2018: Peptilogics receives regulatory approval to initiate first-in-human safety study for therapeutic peptide PLG0206
      • Aug 24, 2018: Peptilogics completes successful pre-IND meeting with the Food and Drug Administration for PLG0206 in Prosthetic Joint Infections
      • Jun 02, 2018: Peptilogics Receives Qualified Infectious Disease Product Designation from FDA for Lead Compound PLG0206 as a Treatment for Prosthetic Joint Infection
      • Oct 29, 2013: Cempra Receives U.S. Orphan Drug Designation for Taksta for Treatment of Prosthetic Joint Infections
      • Dec 14, 2012: Cempra Announces Initiation Of CEM-102 Phase II Clinical Trial In Patients With Prosthetic Joint Infections
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Prosthetic Joint infections, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Prosthetic Joint infections - Pipeline by Armata Pharmaceuticals Inc, H2 2019
  • Prosthetic Joint infections - Pipeline by Arrevus Inc, H2 2019
  • Prosthetic Joint infections - Pipeline by ContraFect Corp, H2 2019
  • Prosthetic Joint infections - Pipeline by Lumobiotics GmbH, H2 2019
  • Prosthetic Joint infections - Pipeline by Peptilogics Inc, H2 2019
  • Prosthetic Joint infections - Pipeline by Sonoran Biosciences Inc, H2 2019
  • Prosthetic Joint infections - Pipeline by Telephus Medical LLC, H2 2019
  • Prosthetic Joint infections - Pipeline by TenNor Therapeutics Ltd, H2 2019
  • Prosthetic Joint infections - Dormant Projects, H2 2019
  • Prosthetic Joint infections - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Prosthetic Joint infections, H2 2019 7
  • Number of Products under Development by Companies, H2 2019 8
  • Number of Products by Targets, H2 2019 11
  • Number of Products by Stage and Targets, H2 2019 11
  • Number of Products by Mechanism of Actions, H2 2019 13
  • Number of Products by Stage and Mechanism of Actions, H2 2019 13
  • Number of Products by Routes of Administration, H2 2019 15
  • Number of Products by Stage and Routes of Administration, H2 2019 15
  • Number of Products by Molecule Types, H2 2019 17
  • Number of Products by Stage and Molecule Types, H2 2019 17